Quantbot Technologies LP Purchases 42,419 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Quantbot Technologies LP lifted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 342.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 54,822 shares of the company’s stock after purchasing an additional 42,419 shares during the period. Quantbot Technologies LP’s holdings in Henry Schein were worth $3,997,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Clarkston Capital Partners LLC lifted its position in shares of Henry Schein by 5.4% during the third quarter. Clarkston Capital Partners LLC now owns 1,397,805 shares of the company’s stock valued at $101,900,000 after purchasing an additional 71,560 shares in the last quarter. Nuance Investments LLC lifted its position in shares of Henry Schein by 22.3% during the third quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock valued at $166,072,000 after purchasing an additional 414,748 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in Henry Schein in the second quarter worth about $46,683,000. SG Americas Securities LLC raised its position in Henry Schein by 1,622.3% in the third quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock worth $33,449,000 after acquiring an additional 432,187 shares during the period. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Henry Schein in the third quarter worth about $515,000. 96.62% of the stock is owned by institutional investors.

Insider Transactions at Henry Schein

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the sale, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. This represents a 22.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $75.00, for a total transaction of $918,000.00. Following the sale, the chief operating officer now owns 87,706 shares of the company’s stock, valued at $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Henry Schein Price Performance

HSIC stock opened at $77.28 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein, Inc. has a one year low of $63.67 and a one year high of $82.63. The stock has a market cap of $9.64 billion, a PE ratio of 31.80, a P/E/G ratio of 2.20 and a beta of 0.87. The firm has a 50 day simple moving average of $71.03 and a two-hundred day simple moving average of $69.76.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the previous year, the business posted $1.32 EPS. On average, analysts predict that Henry Schein, Inc. will post 4.78 EPS for the current fiscal year.

Analysts Set New Price Targets

HSIC has been the topic of several research reports. Robert W. Baird lowered their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research note on Thursday, November 7th. Barrington Research reaffirmed an “outperform” rating and set a $82.00 price objective on shares of Henry Schein in a research note on Wednesday, November 6th. UBS Group reduced their price objective on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Six investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Henry Schein has an average rating of “Moderate Buy” and an average price target of $78.89.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.